Compromised Immunologic Recovery in Treatment-Experienced Patients with HIV Infection Receiving Both Tenofovir Disoproxil Fumarate and Didanosine in the TORO Studies
Open Access
- 15 September 2005
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (6), 901-905
- https://doi.org/10.1086/432879
Abstract
The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period.Keywords
This publication has 5 references indexed in Scilit:
- Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 2005
- Peptide inhibitors of virus—cell fusion: enfuvirtide as a case study in clinical discovery and developmentThe Lancet Infectious Diseases, 2004
- Role of Purine Nucleoside Phosphorylase in Interactions between 2′,3′-Dideoxyinosine and Allopurinol, Ganciclovir, or TenofovirAntimicrobial Agents and Chemotherapy, 2004
- Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral loadAIDS, 2004
- Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial TherapyBlood, 1998